ΝΟΣΟΚΟΜΕΙΑΚΑ ΧΡΟΝΙΚΑ

58Η εποχή της Φαρμακογενωμικής79. CL Atreaga. Can trastuzumab be effective againsttumors with low HER2/Neu (ErbB2)? J Clin Oncol2006; 24:3722−3725.80. A Zaczek, M Wennicka−Jaskrewicz, KP Bielawski, JJaskrewicz et al. Gene copy numbers of HER fam−ily in breast cancer.J Cancer Res Clin Oncol 2008,271−279.81. HJ Broxterman, NH Georgopapadakou,. New Can−cer Therapeutics: target−specific in, cytotoxics out?Drug Res Updates 2004; 7:79−87. ibid 2007; 10:182−193.82. R Ren. Mechanisms of BCR−ABL in the pathogen−esis of chronic myelogenous leukemia. Nat RevCancer 2005; 5:172−183.83. MM Patnaik, A Tefferi, A Pardanani. Kit: moleculeof interest for the diagnosis and treatment of mas−ticytosis and other neoplastic diseases. Cur CancerDrug Tar gets 2007; 7:492−503.84. AM Bennet, E di Angelantonio, Z Ye, F Wensley, ADahlin. Association of apolipoproteinE genotypeswith lipid levels and coronary risk. JAMA 2007;298(11):1300−1311.85. G Li, EB Larson, JA Sonnen, JB Shofer. Statin ther−apy is associated with reduced neuropathologi−cal changes of Altzheimer’s disease. Neurol 2007;69;878−885.86. Treatment outcome of tacrine therapy depends onapolipoprotein genotype and gender of the subjectswith Altzheimer’s disease. Neurol 1998; 50;669−677.87. Ε Βοnnet, A Genoux, J Bernard, J Faurel, P Mas−sip, B Perret. Impact of genetic polymorphisms onthe risk of lipid disorders in patients on anti−HIVtherapy. Clin Chem Lab Med 2007; 45;815−821.88. I Nacher, V Soriano. Overview of the pharmaco−genetics of HIV therapy. J Pharmacogenet 2006;6:234−245.89. PW Hendrick, BC Verrelli. The ground truth for se−lection CCR5−Delta32. Trends Genet 2006; 22:293−296.90. P Biswas, G Tambussi., A Lazzarin. Access denied?The status of co−receptor inhibition to counter HIVentry. Expert Opoin Pharmacother 2007; 8;923−933.91. M Saadutnia, M Tajmirriahi. Hormonal contracep−tives as a risk factor for cerebral venous and sinusthrombosis. Acta Neurol Scand 2007; 115:295−300.92. U Soligsohn, A Lubetsky. Genetic susceptibility to ve−nous thrombosis. N Engl J Med 2001; 344:1222−1231.93. E Papp, V Havasi, J Bene, K Komlosik et al. Glyco−protein IIIA gene polymorphism and aspirin resis−tance: Is there any correlation? Ann Pharmacother2005; 39:1013−1018.94. K Glatter, MH Hamdan,Q Zhang, N Chiamvimon−vat. Drug−induced long QT syndrome: A continuouschallenge in the field. J Cardiovasc Electrophysiol2007; 18:696−697.95. G Millat, P Chevalier, L Restier− Miron, A da Costaet al. Spectrum of pathogenic mutations and asso−ciated polymorphisms in a cohort of 44 unrelatedpatients with LQTS. Clin Genet 2006; 70:214−227.96. http://www.long−qt−syndrome97. a).http://spine.rutgers.edu/cellbio/flash.pcr.htmb).http://pcrlinks.comc). Round table: Which are the best tools for specificclinical applications. Clin Chem Lab Med 2003;41:492−495.98. a).http://www.τrasgenomic.com/flash/DHPLCb) .MW Davis, M Hammarlund. Single nucleotidepolymorphism mapping. Meth Mol Biol 2006;351:75−91c). TA Sivakumaran, K Kucheria, PJ Oefner. DHPLC inthe molecular diagnosis of genetic disorders. CurrSci 2003; 84:2911−2916.99. http://www.microarray.org100. http://www.gene−chips.com101. http://www.bio.davidson.edu/courses/genomics/chip.html102. http://learn.genetics.utah.edu/units/biotech/mi−croarray103. A Waggoner. Fluorescent labels for proteomics andgenomics. Curr Opin Chem Biol 2006; 10:62−66.104. M Ferrari, S Steirri, P Bonini, L Cremonesi. Diag−nostics by microelectronic microchips. Clin ChemLab Med 2003; 41:462−467.105. J van Delden, I Bolt, A Kalis, J Derijks, H Leufkens.Tailor−made pharmaco−therapy: future develop−ments and ethical challenges in the held of phar−maco−genomics. Bioethics 2004: 18:303−321.106. P NW Fangeran. Why should we bother? Ethicaland social issues in individual medicine. Curr DrugTargets 2006; 7:1721−1727.107. Y Joly, BM Knoppres. Pharmacogenomics datasample collection and storage: ethical issues andpolicy approaches. Pharmacogenomics 2006;7:219−222.